Summary:
Click image to enlargeA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder
If you or someone you know is between the ages of 18 and 65 and has not adequately responded to current antidepressant treatment,
May qualify if:
- You have been diagnosed with recurrent Major Depressive Disorder (MDD)
- You are currently experiencing a major depressive episode
- Stable on medication for at least 6 weeks.
Qualified Participants May Receive:
If qualify and decide to participate compensation of $100 for the study visit you complete.
If you qualify to participate in this study, you will receive
- An evaluation by a Board-Certified Psychiatrist,
- Study-related medication
- Study-related medical exams
- No insurance needed